Meeting
2019 ASCO Annual Meeting
Tucatinib, palbociclib, and letrozole in HR+/HER2+ metastatic breast cancer: Report of phase IB safety cohort.
Authors
Elena Shagisultanova
University of Colorado Cancer Center, Aurora, CO
Elena Shagisultanova , Pavani Chalasani , Ursa Abigail Brown-Glaberman , William John Gradishar , Andrew Jacob Brenner , Alison Stopeck , Dexiang Gao , Tessa McSpadden , Peter Kabos , Virginia F. Borges
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
HER2-Positive
Clinical Trial Registration Number
NCT03054363
Citation
J Clin Oncol 37, 2019 (suppl; abstr 1029)
DOI
10.1200/JCO.2019.37.15_suppl.1029
Abstract #
1029
Poster Bd #
110
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Phase 1b study of ONT‑380, an oral HER2-specific inhibitor, in combination with capecitabine (C) and trastuzumab (T) in third line + treatment of HER2+ metastatic breast cancer (MBC).
First Author: Erika Paige Hamilton
Poster
2021 ASCO Annual Meeting
The association of HER2 low expression with the efficacy of CDK4/6 inhibitor in hormone receptor positive HER2 negative metastatic breast cancer.
First Author: Kelvin K H Bao
Poster
2021 ASCO Annual Meeting
Phase I safety and efficacy study of autophagy inhibition with hydroxychloroquine to augment the antiproliferative and biological effects of preoperative palbociclib plus letrozole for estrogen receptor-positive, HER2-negative metastatic breast cancer (MBC).
First Author: Akshara Singareeka Raghavendra
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Pyrotinib combined with SHR6390 in the treatment of refractory advanced HER2-positive gastric cancer or solid tumors: Safety and efficacy results from a phase Id trial.
First Author: Dan Liu